Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.

Subjects: BNT162 Vaccine/BNT162 Vaccine/BNT162 Vaccine/*administration & dosage ; COVID-19/COVID-19/COVID-19/*prevention & control ; ChAdOx1 nCoV-19/ChAdOx1 nCoV-19/ChAdOx1 nCoV-19/*administration & dosage

  • Source: Lancet (London, England) [Lancet] 2021 Dec 18; Vol. 398 (10318), pp. 2277-2287. Date of Electronic Publication: 2021 Nov 11.Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X

Record details

×
Academic Journal

mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network.

Subjects: COVID-19*/COVID-19*/COVID-19*/prevention & control ; COVID-19*/COVID-19*/COVID-19*/epidemiology ; BNT162 Vaccine*/BNT162 Vaccine*/BNT162 Vaccine*/administration & dosage

  • Source: Vaccine [Vaccine] 2024 Jul 11; Vol. 42 (18), pp. 3819-3829. Date of Electronic Publication: 2024 May 06.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities.

  • Authors : Shani M; Department of Family Medicine Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Family Medicine Central District, Clalit Health Service, Rehovot, Israel. Electronic address: .

Subjects: BNT162 Vaccine*/BNT162 Vaccine*/BNT162 Vaccine*/immunology ; BNT162 Vaccine*/BNT162 Vaccine*/BNT162 Vaccine*/adverse effects ; COVID-19*/COVID-19*/COVID-19*/prevention & control

  • Source: Vaccine [Vaccine] 2024 Jul 11; Vol. 42 (18), pp. 3830-3837. Date of Electronic Publication: 2024 May 10.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Comparison of homologous and heterologous inactivated and mRNA vaccination programme against SARS-CoV-2 in dialysis patients.

  • Authors : Yasar E; Department of Nephrology, Gazi University, Faculty of Medicine, Ankara, Turkey.; Yildiz Y

Subjects: COVID-19*/COVID-19*/COVID-19*/prevention & control ; COVID-19*/COVID-19*/COVID-19*/immunology ; Renal Dialysis*/Renal Dialysis*/Renal Dialysis*/adverse effects

  • Source: Nephrology (Carlton, Vic.) [Nephrology (Carlton)] 2024 Jul; Vol. 29 (7), pp. 405-414. Date of Electronic Publication: 2024 Mar 14.Publisher: Blackwell Science Country of Publication: Australia NLM ID: 9615568 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Establishment of human post-vaccination SARS-CoV-2 standard reference sera.

  • Authors : Xiang J; Iowa City Veterans Administration Healthcare System, 601 Highway 6, Iowa City, IA 52246, USA; The University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA.

Subjects: SARS-CoV-2*/SARS-CoV-2*/SARS-CoV-2*/immunology ; Antibodies, Viral*/Antibodies, Viral*/Antibodies, Viral*/blood ; Antibodies, Viral*/Antibodies, Viral*/Antibodies, Viral*/immunology SARS-CoV-2 variants

  • Source: Journal of immunological methods [J Immunol Methods] 2024 Jul; Vol. 530, pp. 113698. Date of Electronic Publication: 2024 May 31.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 1305440 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.

  • Authors : Favresse J; Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium; Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.

Subjects: Antibodies, Neutralizing*/Antibodies, Neutralizing*/Antibodies, Neutralizing*/blood ; Antibodies, Neutralizing*/Antibodies, Neutralizing*/Antibodies, Neutralizing*/immunology ; Antibodies, Viral*/Antibodies, Viral*/Antibodies, Viral*/blood SARS-CoV-2 variants

  • Source: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2024 Jun; Vol. 143, pp. 107028. Date Publisher: Elsevier Country of Publication: Canada NLM ID: 9610933 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3511

Record details

×
Academic Journal

Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus.

  • Authors : Kikuchi J; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.; Kondo Y

Subjects: Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/immunology ; COVID-19*/COVID-19*/COVID-19*/prevention & control ; COVID-19*/COVID-19*/COVID-19*/immunology

  • Source: Immunological medicine [Immunol Med] 2024 Jun; Vol. 47 (2), pp. 76-84. Date of Electronic Publication: 2024 Jan 08.Publisher: Informa UK Limited Country of Publication: England NLM ID: 101736847 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Subjects: COVID-19*/COVID-19*/COVID-19*/prevention & control ; COVID-19*/COVID-19*/COVID-19*/immunology ; Immunocompromised Host*/Immunocompromised Host*/Immunocompromised Host*/immunology

  • Source: The Lancet. Rheumatology [Lancet Rheumatol] 2024 Jun; Vol. 6 (6), pp. e339-e351. Date of Electronic Publication: 2024 May 08.Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101765308 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Response to COVID-19 vaccination in patients on cancer therapy: Analysis in a SARS-CoV-2-naïve population.

  • Authors : Cavic G; Research School of Biology, Australian National University, Canberra, Australia.; Almonte AA

Subjects: COVID-19*/COVID-19*/COVID-19*/prevention & control ; COVID-19*/COVID-19*/COVID-19*/immunology ; Neoplasms*/Neoplasms*/Neoplasms*/immunology

  • Source: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2024 Jun; Vol. 20 (3), pp. 379-385. Date of Electronic Publication: 2024 Jan 14.Publisher: Blackwell Pub. Asia Country of Publication: Australia NLM ID: 101241430 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children <5 Years of Age.

  • Authors : Dalapati T; Medical Scientist Training Program.; Department of Molecular Genetics and Microbiology.

Subjects: BNT162 Vaccine*/BNT162 Vaccine*/BNT162 Vaccine*/immunology ; BNT162 Vaccine*/BNT162 Vaccine*/BNT162 Vaccine*/administration & dosage ; 2019-nCoV Vaccine mRNA-1273*/2019-nCoV Vaccine mRNA-1273*/2019-nCoV Vaccine mRNA-1273*/immunology

  • Source: Pediatrics [Pediatrics] 2024 Jun 01; Vol. 153 (6).Publisher: American Academy of Pediatrics Country of Publication: United States NLM ID: 0376422 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  3,705 results for ""BNT162 Vaccine""